XML 22 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
OPERATING EXPENSES    
Research and development $ 16,360,725 $ 2,839,060
General and administrative 12,344,976 3,974,786
Loss from operations (28,705,701) (6,813,846)
OTHER INCOME/EXPENSE    
Interest income 249
Interest expense (2,051,839)
Non-operating income 33,997
Non-operating expenses (1,472,995) (51,250)
Change in fair value of warrant liability 1,424,603
TOTAL OTHER INCOME/EXPENSE (48,143) (2,069,092)
NET LOSS (28,753,844) (8,882,938)
Cumulative Series A preferred stock dividend requirement (31,250)
NET LOSS available to common shareholders $ (28,753,844) $ (8,914,188)
Weighted average # of shares (in Shares) 29,253,292 6,950,100
Basic loss per common share outstanding (in Dollars per share) $ (0.98) $ (1.28)
Diluted loss per common share outstanding (in Dollars per share) $ (0.98) $ (1.28)